US Hepatorenal Syndrome Therapeutics Market Report 2023 to 2030

US Hepatorenal Syndrome Therapeutics Market Analysis

$ 3999

US Hepatorenal Syndrome Therapeutics (HRS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Renal function improvement and halting further decline are the main objectives of treatment for hepatorenal syndrome. The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations amongst pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.

ID: IN10USRD033 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Sakshi Mantri

Buy Now

US Hepatorenal Syndrome Therapeutics Market Analysis Summary

US Hepatorenal Syndrome Therapeutics Market is valued at around $0.5 Bn in 2022 and is projected to reach $1.21 Bn by 2030, exhibiting a CAGR of 11.63% during the forecast period 2023-2030.

People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Instead of structural kidney disease, it is seen as a functional renal impairment. Although the precise origin of HRS is unknown, it is thought to be predominantly influenced by hemodynamic abnormalities and decreased renal perfusion as a result of changes in systemic and splanchnic circulation. HRS is often divided into Type 1 and Type 2 categories.

The hallmark of type 1 HRS is a rapid and progressive loss in kidney function, frequently accompanied by a brief doubling of blood creatinine (less than two weeks). Without treatment, it has an extremely bad prognosis and a high fatality rate within a few weeks.

A more gradual and sustained loss in kidney function over a longer period of time characterises type 2 HRS. Compared to Type 1 HRS, it has a more varied course and a typically better prognosis.

Clinical criteria and the elimination of any other probable causes of renal dysfunction form the foundation of the diagnosis of HRS. The diagnosis is supported by laboratory tests that measure blood creatinine, urine production, and other indicators of liver and renal function.

The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations among pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa Pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.

Market Dynamics

Market Drivers

Liver disease prevalence: Since HRS is a consequence of advanced liver disease, the need for HRS treatment alternatives is rising as a result of the rising prevalence of liver illness.

Medical Technology Advancements: Ongoing improvements in medical technology, including diagnostic instruments and imaging methods, help to identify HRS earlier and manage it more effectively.

Healthcare Access: Patients with HRS have access to medical specialists and specialised care because healthcare facilities and services are widely available worldwide. The ability to treat HRS patients is further aided by the availability of liver transplant facilities and tertiary care hospitals.

Government Programs and Policies: Government programs, such as Medicare and Medicaid, are crucial in supplying healthcare and paying for HRS-related therapies. The market for HRS medicines is also impacted by regulatory guidelines and clearances from organisations like the Food and Drug Administration (FDA).

Partnerships & Cooperation: Collaborations and collaborations with pharmaceutical firms, academic institutions, and healthcare organisations foster information exchange, clinical trials, and the creation of ground-breaking HRS therapies.

Market Development

The first and only FDA-approved medication, TERLIVAZ, is recommended for the treatment of people with HRS involving a fast decline in kidney function, a serious illness necessitating hospitalisation.

Key players

Novartis AG Gilead Sciences Janssen Pharmaceuticals Bristol-Myers Squibb Pfizer Inc. Roche Holding AG Sanofi AbbVie Intercept Pharmaceuticals Alexion Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Hepatorenal Syndrome Therapeutics Market

By Drugs

Terlipressin
Noradrenaline
Octreotide
Albumin
Other
Others

By Treatment

Liver Transplantation
Renal replacement therapy
Pharmacologic Therapy
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies

By End User

Hospitals
Specialty Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.